The Most Influential People in Vaccines
The 50 Most Influential People in Vaccines

So who are the most influential people in the vaccines industry?

This is the question we took to the industry, and over the last two months we have received hundreds of votes for over 100 different candidates. From Chief Executive Officers and Chief Scientific Officers, to academic researchers and online vaccine advocates, we’ve received votes covering every conceivable part of the vaccines industry.

Unfortunately we didn’t have room to mention everyone who received a nomination in this year’s survey. Instead, here are the 50 most influential people in the vaccines industry, as voted for by the industry itself!
Dr Santosham is a professor of Pediatrics and Pediatric Infectious Diseases at Johns Hopkins, as well as professor of Immunology, International Health and Epidemiology at the Johns Hopkins Bloomberg School of Public Health. He is a renowned expert in oral rehydration therapy, for which his research is world-renowned. He has evaluated numerous paediatric vaccines among the Navajo and Apache Indian populations including Hib, Hepatitis A, rotavirus and pneumococcal vaccines. In April 2014 Dr Santosham was awarded the Albert B. Sabin Gold Medal for his work to prevent H. Influenza type B diseases.

Dr Michael, a Colonel in the United States Army Medical Corps, entered his Army service in 1989 in WRAIR’s Department of Vaccine Research. Dr. Michael was appointed Director of MHRP in January 2006, and guided MHRP through the completion of the RV144 HIV prime-boost vaccine study. This clinical trial, an international collaboration that involved more than 16,000 Thai volunteers, provided the world’s first demonstration that a preventive HIV vaccine was possible.

Chip Clark joined Genocea Biosciences in 2010 as president. Prior to this, he co-founded Vanda pharmaceuticals, which had completed a $200 million licensing deal with Novartis in 2010. At Genocea, Clark helped the company secure a $35 million Series B funding round from the likes of Johnson and Johnson and other pharmaceutical companies. In 2011, he was named CEO of Genocea. The company has raised $61 million so far, which it is using to advance five vaccine programs.

In 2013 Karen Ernst re-launched Voices for Vaccines, a parent-driven organization supported by scientists, doctors, and public health officials that provides parents science-based information about vaccines and vaccine-preventable disease. Prior to this, she was an adjunct associate professor of English literature at St. Catherine University, Minnesota.

Dr Santosham is a professor of Pediatrics and Pediatric Infectious Diseases at Johns Hopkins, as well as professor of Immunology, International Health and Epidemiology at the Johns Hopkins Bloomberg School of Public Health. He is a renowned expert in oral rehydration therapy, for which his research is world-renowned. He has evaluated numerous paediatric vaccines among the Navajo and Apache Indian populations including Hib, Hepatitis A, rotavirus and pneumococcal vaccines. In April 2014 Dr Santosham was awarded the Albert B. Sabin Gold Medal for his work to prevent H. Influenza type B diseases.
Mark Lacy is the founder and CEO of Benchmark Research, a clinical trials service provider. Since its founding in 1997, the company has expanding from providing clinical trial services in just Fort Worth Texas, to now providing services in 6 dedicated research centers across the United States. In 2010, he was selected as a finalist by Entrepreneur magazine as the Established Entrepreneur of 2010.

Dr. David Salisbury is responsible for the UK’s national immunisation programme. In addition to his UK responsibilities, he works extensively with the WHO on the Global Programme for Vaccines. He was Chairman of the WHO Strategic Advisory Group of Experts on Vaccines from 2005 to 2010, is Chairman of the European Region Certification Commission for Poliomyelitis Eradication, and is a member of Polio Elimination Certification Commission for two further WHO regions.

Dr. Samuel Katz is a paediatrician and virologist whose career has been devoted to infectious disease research, focusing principally on vaccine research and development. He has chaired the Committee on Infectious Diseases of the American Academy of Pediatrics, the Advisory Committee on Immunization Practices at the CDC, the Vaccine Priorities Study at the Institute of Medicine, and several WHO and CVI vaccine and HIV panels. Earlier in his career Dr Katz worked with Nobel Laureate John F. Enders at Boston Children’s Hospital where they developed the now widely used attenuated measles virus vaccine.

Melody Ann Butler started the Nurses Who Vaccinate Facebook page in 2011 and continues to use it to respond to online parenting forums that publicize inaccurate information about vaccines. Her initiatives caught the attention of The Wall Street Journal, and she has also been invited to participate with other pro-vaccine organizations, including Every Child by Two, Vaccinate Your Baby, and Shot of Prevention. She is also a global health champion for the Shot@Life foundation, a United Nations campaign to immunize children around the globe.

Professor David Salisbury is responsible for the UK’s national immunisation programme. In addition to his UK responsibilities, he works extensively with the WHO on the Global Programme for Vaccines. He was Chairman of the WHO Strategic Advisory Group of Experts on Vaccines from 2005 to 2010, is Chairman of the European Region Certification Commission for Poliomyelitis Eradication, and is a member of Polio Elimination Certification Commission for two further WHO regions.
<table>
<thead>
<tr>
<th>#</th>
<th>Name</th>
<th>Title and Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>42</td>
<td>Dr Mario Monterio</td>
<td>Professor of Vaccines and Carbohydrates, University of Guelph, Ontario. His latest research has covered various vaccines, including a Diarrhea vaccine, which has entered a phase 1 human clinical trial, and a vaccine target for Clostridium bolteae, an autism-associated bacterium. His research team includes 3 PhD students, 4 M.Sc students and a Post-Doctoral Associate.</td>
</tr>
<tr>
<td>41</td>
<td>Dr Marie-Paule Kieny</td>
<td>Assistant Director-General of Health Systems and Innovation, World Health Organisation. Appointed in November 2012, Dr Kieny was previously WHO Assistant Director-General for Innovation, Information, Evidence and Research. Prior to this, Dr Kieny directed the WHO Initiative for Vaccine Research since its inception in 2001. Under her leadership the development of new vaccines against meningitis, and pandemic influenza in developing countries all took place. Before coming to WHO, Dr Kieny held top research positions at Transgene, and the Institut national de la santé et de la recherche médicale (INSERM).</td>
</tr>
<tr>
<td>40</td>
<td>Dr Robin Robinson</td>
<td>Director, Biomedical Advanced Research and Development Authority, US Department of Health and Human Services. Dr Robinson was appointed in 2008 as the first director of the newly created Biomedical Advanced Research and Development Authority (BARDA), and Deputy Assistant Secretary in the Office of the Assistant Secretary for Preparedness and Response within HHS. Dr Robinson led the US’s effort to develop and manufacture the largest volume of vaccines in U.S. history, a response to the 2009 H1N1 pandemic. Dr Robinson previously served as the Director for the Influenza &amp; Emerging Disease Program within BARDA and its predecessor agency at HHS.</td>
</tr>
<tr>
<td>39</td>
<td>Dr Kathryn Edwards</td>
<td>Professor of Pediatrics, and Director, Vanderbilt Vaccine Research Program, Vanderbilt University. Dr Edwards is an expert in vaccinology, with numerous publications in the fields of pertussis, pneumococcus, and influenza. A member of the Institute of Medicine, Dr Edwards is Principal Investigator of the NIH-funded Vanderbilt Vaccine and Treatment Evaluation Unit (VTEU) and the CDC-funded Clinical Immunization Safety Assessment (CISA) Network.</td>
</tr>
</tbody>
</table>

Tweet “The Most Influential People in Vaccines”
Dr Moncef Slaoui
Chairman, Research and Development
GlaxoSmithKline

Dr Moncef joined GSK Vaccines in 1988, moving on to Worldwide Business Development for pharmaceutical products before his appointment to lead R&D in 2006. He was also given overall responsibility for GSK’s Oncology Business in 2010; for GSK Vaccines in 2011; and for all Global Franchises in 2012. With over 100 scientific papers and presentations published, prior to joining GSK, Moncef was Professor of Immunology at the University of Mons, Belgium.

Dr Kathleen Neuzil
Program Leader, Vaccine Access and Delivery
PATH

Dr Neuzil directs PATH’s activities that focus on developing and advancing strategies, technologies, and interventions that help move research achievements in immunization into routine use in the field. She has provided technical and leadership guidance for vaccine projects including work on a rotavirus vaccine, HPV, Japanese encephalitis and influenza. Prior to joining PATH, Dr Neuzil held positions at the University of Washington, and Vanderbilt University, positions in domestic and international policy, and membership on the CDC advisory committee on immunisation practices.

Dr Marie-Pierre Préziosi
Project Director of the Meningitis Vaccine Project
World Heath Organisation & PATH

Marie-Pierre Préziosi was appointed director of the PATH/WHO Meningitis Vaccine Project in March 2012. A member of the MVP team since 2003, Marie-Pierre Préziosi had most recently served as director of clinical development for MVP as part of her role as medical officer at WHO. In her early years with MVP, Marie-Pierre Préziosi contributed documentation on epidemic meningitis and related vaccine use for informing development of a new meningococcal A conjugate vaccine and introduction strategies. As MenAfriVac moved to the clinical phase, she was appointed to lead MVP clinical research activities.

Dr David Weiner
Professor of Pathology and Laboratory Medicine
University of Pennsylvania

Dr Weiner’s research in the area of Molecular Immunology has focused extensively on the development of gene-based vaccines and immune therapies. His laboratory was the first to move DNA vaccines to human clinical studies establishing their initial safety and immunogenicity. He is also very active in teaching and training of students, fellows, and junior faculty. He chairs the popular Gene Therapy and Vaccines Program at the University of Pennsylvania, and co directs the Tumor Virolgy Program of the Abramson Cancer Center at the University of Pennsylvania.

Follow @VaccineNation
Mr Shari Narendra Modi
Prime Minister of India

The current Prime Minister of India, Shri Narendra Modi, announced on the 3rd of July 2014 the decision to introduce four new vaccines as part of India’s Universal Immunization Programme. Rotavirus, rubella and polio (injectable) vaccines will drive India towards their Millennium Development Goal to reduce child mortality by two-thirds by 2015 and keep polio at bay. In addition, an adult vaccine against Japanese encephalitis will be introduced in some districts.

Dr Annie De Groot
Co-founder, Chief Executive Officer, Chief Scientific Officer, EpiVax

Dr De Groot and Bill Martin founded EpiVax in 1998 to use bioinformatics to design epitope-driven vaccines, and expanded to offer immunogenicity screening services for protein therapeutics. She has also contributed to the Yale HIV in Prison program providing medical treatment to inmates, founded the GAIA Vaccine Foundation for improving global AIDS treatment, and founded a free clinic in Rhode Island, Clinica Esperanza.

Dr Barney Graham
Deputy Director, Vaccine Research Centre, National Institute of Allergy and Infectious Disease (NIAID)

Dr Barney Graham is the Deputy Director of the National Institute of Allergy and Infectious Disease. Prior to this, he has held positions as Chief Resident at both the Metro General hospital and the Vanderbilt hospital. His contributions to AIDS and HIV research were significant, and he even diagnosed on of the first two cases of AIDS in Tennessee as chief resident at Metro General.

Dr Bruce Aylward
Assistant Director-General for Polio Emergencies and Country Collaboration, World Health Organisation

Dr Aylward brings together the WHO’s work in polio eradication, humanitarian response and country cooperation. Dr Aylward is a physician and epidemiologist. He has authored over 100 peer-reviewed scientific research papers, as well as book chapters on immunisation. He joined the WHO in 1992 as a Medical Officer, where he worked for 7 years with national immunisation programmes across the globe. Since 1998, he has been responsible for overseeing and coordinating all polio eradication activities across WHO’s Global polio Eradication Initiative Partnership.

Tweet “The Most Influential People in Vaccines”
Dr Bruce Gellin is one of the US's top experts on vaccines and infectious diseases. NVPO was created by Congress to provide leadership and coordination among Federal agencies and other immunization stakeholders. Before joining NVPO in 2002, Dr Gellin was the director of the National Network for Immunization Information, an organization he founded to be a resource of up-to-date, authoritative information about vaccines and immunizations.

Dr Weber has been with GSK Vaccines for more than 17 years. In 2000 he was appointed as Vice President and Operations Director of GSK France. In 2002, Weber was appointed Vice President and then served as Chairman and CEO of GlaxoSmithKline France between 2003 and 2008. In 2008, he was appointed Senior Vice-President and Regional Director, Asia Pacific at GlaxoSmithKline Singapore. Since January 2011, he has been President Designate of GSK Vaccines and began his term as President in Spring 2012.

Dr Bright, an immunologist in training, was appointed VP of Vaccine Research in 2006. Prior to this, he has had more than 15 years of experience as a researcher in influenza vaccines and antivirals. He also served in the Influenza Branch of the CDC’s Antiviral Drug Program. Dr Bright held the position of Senior Research Scientist and Project Manager, Vaccine and Immunology Programs at Althea Therapeutics.

Dr Kim, a Colonel in the United States Army Medical Corps, started his military career in the Air Force, assigned to the Department of Retroviral Research. After a brief exodus, he entered Army service in 2000 in the Department of HIV Vaccine Research, Division of Retrovirology, WRAIR. Dr Kim’s research interests include HIV molecular epidemiology, host genetics, and HIV vaccine development. He serves as a reviewer for scientific journals and has served on consultations for the World Health Organization and the Global HIV/AIDS Vaccine Enterprise.
Melinda Gates is co-chair of the Bill & Melinda Gates Foundation. Along with co-chair Bill Gates, she shapes and approves the strategic direction of the foundation. From gun violence to vaccination, the foundation has pumped billions into the world’s poorest and most vulnerable areas, including billions of the Gates’ personal funds. The foundation has poured millions into both R&D as well as increasing vaccine coverage across the world. Their commitment to vaccines has seen collaborations with Sanofi Pasteur and GSK investigating thermostability, as well as a $138m investment in malaria vaccine R&D.

Dr. Jadhav is the Executive Director of the Serum Institute of India, one of the largest vaccine manufacturers in the world. He also led the development and introduction of a Meningococcal A conjugate vaccine in sub-Saharan Africa. Dr. Jadhav was president of the Developing Countries Vaccine Manufacturers’ Network (DCVWN) from 2003-2008. He is currently a member of GAVI Board, EVI Board of Stakeholders, FastVac, member of the Program & Policy Committee of GAVI. He is also associated with Sabin Vaccine Institute’s Task Force, WHO IVR and Decades of Vaccines.

Dr. John Shiver is the Senior Vice-President of Research and Development at Sanofi Pasteur. He also serves as Vice-President of Worldwide Basic Research and Franchise Head of Vaccines at Merck. He leads a team working to develop novel vaccines against a broad range of diseases, including HIV/AIDS, human papillomavirus, zoster, influenza and bacterial infections. He has co-authored 24 patents covering vaccine development.

Anthony S. Fauci is an immunologist who has made substantial contributions to research in the areas of HIV/AIDS and other immunodeficiencies, both as a scientist and as the head of the NIAID. He oversees an extensive research portfolio of basic and applied research to prevent, diagnose, and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism.
Dr Kathrin Jansen is the Senior Vice President and Chief Scientific Officer of Vaccine Research and Early Development at Pfizer. In 2006, she joined Wyeth as senior vice president, which is now part of Pfizer. In this role, she supported the paediatric licensure of Prevnar 13, as well as its adult licensure. Her and her team have created a vaccine against Staphylococcus aureus, which is now in phase 2. Prior to joining Wyeth, Dr Jansen was the Chief Scientific Officer of VaxGen.

Dr Akira Homma is the current chairman of Bio-Maguinhos, based in Brazil. Previously, he was the president for the Japan Society for Dementia Care. He was also a board member of the Japan Society for Geriatric Psychiatry. He studied medicine in Japan, graduating in 1973.

Mr Erck was appointed President and CEO of Novavax in April 2011. From 2000-2008, he was president and CEO of Iomai corporation. He led the company through to IPO and a merger with Intercell, an Austrian vaccine company. He also led the company through the development of an infectious disease product candidate. Prior to Iomai, Mr Erck was President and CEO of Procept, and before this held positions at Genzyme and Baxter International. He attended the University of Illinois for his undergraduate degree, and received his MBA from the University of Chicago Graduate School of Business.
Dr Manon Cox, President and CEO of the Protein Science Corporation, joined the company in 1998 as Director of Business Development. She also serves on the Scientific Advisory Boards of Pall BioPharmaceuticals and ICubed, the Board of Directors of United Way, Meriden & Wallingford, and the Netherlands-America Foundation and its Education Committee. Previously, she was with Gist-Broca, a Dutch company specialising in fermentation. Prior to Gist-broca, she worked as a Molecular Biologist on the development of a PCR screening test for cervical cancer at the University of Amsterdam.

Dr Reiss is a Professor at the University of California Hastings College of Law. Dr Reiss has come to the attention of the vaccines industry through her outspoken defence of vaccines on the internet. From writing about the legal rights of unvaccinated children, through engaging with the fierce anti-vaccine mob, Ageofautism.com even have a page dedicated to her…

Dr Reiss received her PhD from the Jurisprudence and Social Policy program in UC Berkeley. Her research is currently focused on legal issues related to vaccines, including exemption laws and tort liability to non-vaccination.

Cynthia Dukes, VP and therapeutic and operations advisor for ICON, has over 35 years of diverse clinical experience. After practicing as a medical technologist in general laboratory medicine and as a PA in primary care, Cynthia began her research career as the clinical team leader at Baylor College of Medicine’s vaccine and Respiratory Diseases Research Center. After this, she joined Sanofi Pasteur for ten years. Throughout her career, she has supported multiple IND submissions and product approvals.

Cyrus Poonawalla is the Chairman of the Poonawalla Group, which owns the Serum Institute of India. The Serum Institute of India is the world’s largest producer of vaccines, making more than a billion doses annually from a factory in Pune, western India. He is listed by Forbes as being the 10th richest man in India.
Making a strong leap from #50 last year, down to the mid teens in 2014, Ewan McGregor is on a mission to the ends of the earth to immunise some of the hardest-to-reach children in the world, following two vaccine trails supported by Unicef. After India and Nepal, Ewan’s second cold chain mission was in the Republic of Congo where he continued to bring vaccines to families of the most remote and vulnerable areas in the Congo.

Dr Berkley, a medical epidemiologist by training, is the CEO of the GAVI Alliance as well as the former President and CEO of the International AIDS Vaccine Initiative. Under his leadership, IAVI implemented a global advocacy programme that assured that vaccines receive prominent attention in the media and in the political world. Prior to founding IAVI in 1996, Dr Berkley was an officer at The Rockefeller Foundation, worked at the CDC, as well as the Task Force for Child Survival at the Carter Center.

Steve Davis is the president and CEO of PATH, an international non-profit organisation. His commitment to human rights and global development grew from his early work on refugee programs and policies. Before joining PATH, he had been the director of social innovation for McKinsey and Company and interim CEO of the Infectious Diseases Research Institute. Steve Davis sits on multiple advisory groups, including the World Economic Forum’s Global Agenda Council on Social Innovation, the Clinton Global Initiative’s Global Health Advisory Board and more.

Ralf Clemens, PHD, is the Senior Vice-President at Takeda Pharmaceuticals Ltd, a position he has held since March 2012, after working as Head of Global Development Vaccines at Novartis for 6 years. Before joining Novartis, he was with Glaxo Smith Kline for 24 years.
<table>
<thead>
<tr>
<th>No.</th>
<th>Name</th>
<th>Title</th>
<th>Achievement</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>Dr Emilio Emini</td>
<td>Senior Vice President and Chief Scientific Officer, Vaccine Research Pfizer</td>
<td>Successfully led the development of vaccines to eradicate smallpox, polio, and measles in Latin America.</td>
</tr>
<tr>
<td>9</td>
<td>Dr George Siber</td>
<td>Executive Chairman, Genocea Biosciences</td>
<td>Pioneered the development of vaccines to prevent respiratory diseases.</td>
</tr>
<tr>
<td>8</td>
<td>Dr Ciro de Quadros</td>
<td>Executive VP, Director of Vaccine Advocacy and Education, Sabine Vaccine Institute</td>
<td>Eradicated smallpox, polio, and measles in Latin America.</td>
</tr>
<tr>
<td>7</td>
<td>Dr Paul Offit</td>
<td>Director, Vaccine Education Centre, Children’s Hospital of Philadelphia</td>
<td>Developed vaccines for rotavirus, measles, and pneumococcal diseases.</td>
</tr>
</tbody>
</table>

Dr Emilio Emini, Ph.D., is Senior Vice President and Chief Scientific Officer of Vaccine Research at Pfizer Inc., a position into which he transitioned subsequent to Pfizer’s acquisition of Wyeth Pharmaceuticals in late 2009. Dr Emini joined Wyeth as Executive Vice President of Vaccine Research and Development in November 2005. At Wyeth, he led the R&D efforts that resulted in licensure of our second-generation vaccine for the prevention of pneumococcal disease.

Dr Siber was previously Executive Vice President and Chief Scientific Officer of Wyeth Vaccines where he oversaw the development and approval of multiple widely-used childhood vaccines, including Prevnar, the predecessor to Pfizer’s best-selling Prevnar 13. Prior to Wyeth, Dr Siber was Director of the Massachusetts Public Health Biologic Laboratories and a Harvard Medical School Associate Professor of Medicine at Dana Farber Cancer Institute. Dr Siber is now the executive director and chairman of Genocea’s scientific advisory board, and also sits on a number of PATH committees.

Dr Emini joined Wyeth as Executive Vice President of Vaccine Research and Development in November 2005. At Wyeth, he led the R&D efforts that resulted in licensure of our second-generation vaccine for the prevention of pneumococcal disease.

Sadly, Dr Quadros died in May of this year at the age of 74. Before joining Sabin in 2003, Dr de Quadros was the Director of the Division of Vaccines and Immunization at the Pan American Health Organization. He also served as the World Health Organization’s Chief Epidemiologist for the Smallpox Eradication Program in Ethiopia from 1970 to 1976 where he implemented a nationwide “surveillance and containment” strategy, a world first. Dr Quadros is often credited with having eradicated smallpox single-handedly from Brazil, measles from the Americas, and polio in Latin America.

Dr Paul A. Offit is a professor of vaccinology and paediatrics at the University of Pennsylvania. He is also Chief of the Division of Infectious Diseases at the Children’s Hospital of Philadelphia. Dr Offit specialises in infectious diseases and is an expert on vaccines, immunology, and virology. He is the co-inventor of a rotavirus vaccine that has been credited with saving hundreds of lives every day. Previously he was a member of the CDC advisory committee on immunisation practices. Dr Offit is also a board member of every child by two, and a founding member of the Autism Science Foundation.
Dr Orin Levine
Director of Vaccine Delivery
Bill and Melinda Gates Foundation

Dr Stan Plotkin
Emeritus Professor
University of Pennsylvania
Adjunct Professor
Johns Hopkins University

Dr Levine is the Executive Director of the International Vaccine Access Center, the co-chair of the Pneumococcal Awareness Council of Experts (PACE), and he is a professor at the John Hopkins Bloomberg School of Public Health. Dr Levine also serves as Director of Vaccine Delivery at the Bill and Melinda Gates Foundation, where he leads the Foundation’s efforts to accelerate the introduction of new vaccines and related technologies and to improve routine immunization systems around the world.

He is the Foundation’s focal point for engagement with the GAVI Alliance, whose mission is saving children’s lives by increasing access to immunization in poor countries. Previously, Dr Levine was the President the American Society of Tropical Medicine and Hygiene. Dr Levine received his undergraduate Bachelors degree from Gettysburg College in Gettysburg, Pennsylvania. He continued his studies at the John Hopkins Bloomberg School of Public Health, where he received a PhD in epidemiology. After receiving his PhD, he worked for the CDC as an epidemic intelligence service officer.

Previously, Dr Levine has been President of the Committee on Global Health at the American Society of Tropical Medicine & Hygiene as well as Co-Chair of the Pneumococcal Awareness Council of Experts (PACE).

Dr Levine regularly writes about health issues and news for the Huffington Post. He has co-authored over 70 research papers covering pneumonia and meningitis, and has written book chapters about these topics too.

Dr Plotkin is Emeritus Professor of the University of Pennsylvania and Adjunct Professor of John Hopkins University. Dr Plotkin is also a member of the scientific advisory board for Hookipa Biotech.

Until 1991, he was Professor of Pediatrics and Microbiology at the University of Pennsylvania, Professor of Virology at the Wistar Institute and at the same time, Director of Infectious Diseases and Senior Physician at the Children’s Hospital of Philadelphia. In 1992, he left the University to join the vaccine manufacturer Pasteur-Mérieux Connaught, where for seven years he was Medical and Scientific Director.

The same company is now named Sanofi Pasteur. He is now consultant to vaccine manufacturers, biotechnology companies and non-profit research organizations. Earlier in his career, he did an internship at Cleveland Metropolitan General Hospital, a residency in paediatrics at the Children’s Hospital of Philadelphia and the Hospital for Sick Children in London and three years in the Epidemic Intelligence Service of the Centers for Disease Control of the US Public Health Service.
4  Dr Rino Rappuoli  
Head of R&D  
Novartis Vaccines

Rino Rappuoli is Global Head of Vaccines Research at Novartis Vaccines and Diagnostics. Prior to this he was head of Research & Development at Sclavo and then head of vaccine research and Chief Scientific Officer of Chiron Corporation. Rappuoli has spent his career developing vaccines for pertussis, meningitis, and Helicobacter pylori and is jointly responsible for engineering the carrier protein used in many conjugate vaccines.

Several molecules he worked with became part of licensed vaccines, including: CRM197 used in H. influenzae, N. meningitides and pneumococcus vaccines; an acellular vaccine against pertussis containing a genetically detoxified pertussis toxin; the first conjugate vaccine against meningococcus C and later against meningococcus ACYW; the MF59 used in a vaccine against pandemic influenza; and the genome-derived vaccine against meningococcus B currently under review by European and Canadian regulatory agencies.

He was elected a member of the US National Academy of Sciences and the European Molecular Biology Organization. Awards conferred include: Paul Ehrlich and Ludwig Darmstaedter Prize (1991), the Gold Medal by the Italian President (2005), the Albert B. Sabin Gold Medal (2009), the Lifetime Achievement Award from the Institute of Human Virology in Maryland (2010), and the Excellence Award from the European Society of Clinical Microbiology and Infectious Diseases (2011).

3  Dr Stephen Hoffman  
Founder, Chief executive Officer,  
Chief Scientific Officer  
Sanaria

Dr Hoffman is the Founder, and Chief Executive and Scientific Officer of Sanaria Inc., a company dedicated to developing a whole sporozoite malaria vaccine.

From 1987-2001 he was Director of the Malaria Program at the Naval Medical Research Center where he and his team were leaders in the sequencing of the Plasmodium falciparum genome and conducted the first studies in the world that showed that DNA vaccines elicited killer T cells in humans.

In 2001 Dr Hoffman retired from the Navy and joined Celera Genomics as Senior Vice President to create a program to utilize genomics and proteomics to produce new biopharmaceuticals. He established this program and organized the effort that sequenced the genome of the mosquito responsible for most transmission of malaria in Africa, Anopheles gambiae. He left Celera in August 2002 to found Sanaria. He is the most highly cited author in the world for scientific papers on malaria published between 1995 and 2005.

Sanaria caught headlines earlier this year after launching a $250,000 crowdfunding campaign to help finance a number of mosquito dissecting robots. Whilst ultimately unsuccessful, the campaign demonstrated Sanaria’s and Hoffman’s innovative approach to development that involves the public in the search for a cure against the world’s biggest killer.
Dr Monath has devoted his nearly 30-year career to the fight against infectious disease through his work in the military, corporate, academic and investment sectors. In addition to his role at PaxVax, Dr Monath is a Partner in the Pandemic and Biodefense Fund at Kleiner Perkins Caufield & Byers and is a Director of Sentinext plc, Rapid MicroBiosystems Inc., and U.S. Biologics Inc. He is also Adjunct Professor at Harvard School of Public Health.

From 1992 to 2006, Dr Monath was Chief Scientific Officer and Executive Director at Acambis, which was acquired by Sanofi Pasteur in 2008 for £285m. At Acambis, Dr Monath pioneered the development of ChimeriVax vaccines against dengue, West Nile, Japanese encephalitis (using yellow fever as a live vector) vaccines against yellow fever, Clostridium difficile, Helicobacter pylori, as well as a cell based smallpox vaccine featured in the US stockpile.

In 1992, Dr Monath retired as a U.S. Army colonel following 24 years in the uniformed services. From 1973 to 1988, he served as director of the Division of Vector-Borne Viral Diseases at the Centers for Disease Control; and from 1989 to 1992, he served as chief of the Virology Division, U.S. Army Medical Research Institute of Infectious Diseases.

PaxVax currently has a strong and diverse vaccine pipeline, aimed squarely at currently unoccupied markets. Using licenced technologies, as well as their own Ad4/Ad7 vectors and their A549 cell substrate, the team have vaccines for cholera, H5N1, Anthrax, HIV, and Dengue all in the works.

Recently, the company has acquired the FDA approved typhoid vaccine, cure cells Vivotif, which was tied to a successful $62 million funding round.
Bill Gates is co-chair of the Bill & Melinda Gates Foundation. Along with co-chair Melinda Gates, he shapes and approves grant making strategies, advocates for issues focused on by the foundation, and helps set the overall direction of the organization.

Bill and Melinda Gates work together to give opportunities to the world’s most disadvantaged people by collaborating with grantees and partners. Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. In developing countries, it focuses on improving people’s health and giving them the chance to lift themselves out of hunger and extreme poverty. Vaccines have played a major role in the foundation’s supported initiatives.

As of the May last year, Bill had donated $28,000,000,000 ($28b) to the foundation. The foundation operates by the exclusive goal of maximising the return on their investment in terms of human life.

The foundation has poured millions into both R&D as well as increasing vaccine coverage across the world. Their commitment to vaccines has seen collaborations with Sanofi Pasteur and GSK investigating thermostability, as well a $138m investment in malaria vaccine R&D.